SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Maenpaa Johanna)
 

Sökning: WFRF:(Maenpaa Johanna) > The use of granuloc...

The use of granulocyte colony stimulating factor (G-CSF) and management of chemotherapy delivery during adjuvant treatment for early-stage breast cancer-Further observations from the IMPACT solid study

Maenpaa, Johanna (författare)
Univ Tampere, Tampere Univ Hosp, FIN-33101 Tampere, Finland.
Varthalitis, Ioannis (författare)
Chania Gen Hosp, Khania, Greece.
Erdkamp, Frans (författare)
Orbis Med Ctr, Sittard, Netherlands.
visa fler...
Trojan, Andreas (författare)
Brust Zentrum Zurich, Zurich, Switzerland.
Krzemieniecki, Krzysztof (författare)
Jagiellonian Univ, Oncol Clin, PL-31007 Krakow, Poland.
Lindman, Henrik (författare)
Uppsala universitet,Experimentell och klinisk onkologi
Bendall, Kate (författare)
Amgen Ltd, Uxbridge, Middx, England.
Vogl, Florian D. (författare)
Amgen Inc, Thousand Oaks, CA 91320 USA.
Verma, Shailendra (författare)
Ottawa Reg Canc Ctr, Ottawa, ON K1Y 4K7, Canada.
visa färre...
Univ Tampere, Tampere Univ Hosp, FIN-33101 Tampere, Finland Chania Gen Hosp, Khania, Greece. (creator_code:org_t)
Elsevier BV, 2016
2016
Engelska.
Ingår i: Breast. - : Elsevier BV. - 0960-9776 .- 1532-3080. ; 25, s. 27-33
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Objective: To investigate the use and impact of granulocyte colony-stimulating factors (G-CSF) on chemotherapy delivery and neutropenia management in breast cancer in a clinical practice setting. Methods: IMPACT Solid was an international, prospective observational study in patients with a physician-assessed febrile neutropenia (FN) risk of >= 20%. This analysis focused on stages I-III breast cancer patients who received a standard chemotherapy regimen for which the FN risk was published. Chemotherapy delivery and neutropenia-related outcomes were reported according to the FN risk of the regimen and intent of G-CSF use. Results: 690 patients received a standard chemotherapy regimen; 483 received the textbook dose/schedule with a majority of these regimens (84%) having a FN risk >= 10%. Patients receiving a regimen with a FN risk >= 10% were younger with better performance status than those receiving a regimen with a FN risk < 10%. Patients who received higher-risk regimens were more likely to receive G-CSF primary prophylaxis (48% vs 22%), complete their planned chemotherapy (97% vs 88%) and achieve relative dose intensity >= 85% (93% vs 86%) than those receiving lower-risk regimens. Most first FN events (56%) occurred in cycles not supported with G-CSF primary prophylaxis. Conclusion: Physicians generally recommend standard adjuvant chemotherapy regimens and were more likely to follow G-CSF guidelines for younger, good performance status patients in the curative setting, and often modify standard regimens in more compromised patients. However, G-CSF support is not optimal, indicated by G-CSF primary prophylaxis use in < 50% of high-risk patients and observation of FN without G-CSF support.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Nyckelord

Granulocyte colony-stimulating factor
Neutropenia
Chemotherapy delivery
Clinical practice

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

  • Breast (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy